Basit öğe kaydını göster

dc.contributor.authorAl-Shamsi, Humaid O.
dc.contributor.authorAbdel-Wahab, Reham
dc.contributor.authorHassan, Manal M.
dc.contributor.authorShalaby, Ahmed S.
dc.contributor.authorDahbour, Ibrahim
dc.contributor.authorLacin, Sahin
dc.contributor.authorMahvash, Armeen
dc.contributor.authorOdisio, Bruno C.
dc.contributor.authorMurthy, Ravi
dc.contributor.authorAvritscher, Rony
dc.contributor.authorAbdelsalam, Mohamed E.
dc.contributor.authorRashid, Asif
dc.contributor.authorVauthey, Jean-Nicolas
dc.contributor.authorAloia, Thomas A.
dc.contributor.authorConrad, Claudius
dc.contributor.authorChun, Yun Shin
dc.contributor.authorKrishnan, Sunil
dc.contributor.authorDas, Prajnan
dc.contributor.authorKoay, Eugene J.
dc.contributor.authorAmin, Hesham M.
dc.contributor.authorYao, James C.
dc.contributor.authorKaseb, Ahmed O.
dc.date.accessioned2019-12-10T11:15:18Z
dc.date.available2019-12-10T11:15:18Z
dc.date.issued2017
dc.identifier.issn0030-2414
dc.identifier.urihttps://doi.org/10.1159/000455957
dc.identifier.urihttp://hdl.handle.net/11655/15206
dc.description.abstractBackground: Hepatocellular carcinoma (HCC) prognosis depends on clinicopathological features in addition to the treatment provided. We aimed to assess the natural history of TNM stage I HCC tumors which received different treatment over a period of 20 years. Methods: Between 1992 and 2011, a total of 397 stage I HCC patients were included. Detailed information was retrieved from MD Anderson Cancer Center patients' medical records. The Kaplan-Meier method was used to calculate patients' overall survival (OS). Cox regression analysis was used to calculate the estimated hazard ratio and 95% confidence interval of different prognostic factors. Results: Out of 397 patients, 67.5% were males, 42.8% had hepatitis-related HCC, and 59.7% had underlying cirrhosis. After adjustment for confounding factors, we found that all therapeutic modalities were associated with a significant mortality rate reduction with an OS of 63, 42.03, 34.3, and 22.1 months among patients treated with surgery, ablation, local, and systemic therapy, respectively. A restricted analysis of cirrhotic and noncirrhotic patients showed that ablative and local therapy were significantly associated with a longer OS compared to systemic therapy. Conclusion: TNM stage I HCC patients have a favorable prognosis regardless of the type of treatment. Notably, ablative and local therapy significantly improved OS compared to systemic therapy. (C) 2017 S. Karger AG, Basel
dc.language.isoen
dc.publisherKarger
dc.relation.isversionof10.1159/000455957
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectOncology
dc.titleNatural History Of T1N0M0 Hepatocellular Carcinoma: Large-Scale Study In The United States
dc.typeinfo:eu-repo/semantics/article
dc.relation.journalOncology
dc.contributor.departmentİç Hastalıkları
dc.identifier.volume93
dc.identifier.issue4
dc.identifier.startpage233
dc.identifier.endpage242
dc.description.indexWoS


Bu öğenin dosyaları:

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster